➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Johnson and Johnson
Express Scripts
Moodys
Boehringer Ingelheim

Last Updated: April 10, 2021

DrugPatentWatch Database Preview

Litigation Details for Network Protection Sciences, LLC v. Juniper Networks, Inc. (N.D. Cal. 2012)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Network Protection Sciences, LLC v. Juniper Networks, Inc. (N.D. Cal. 2012)

Docket   Start Trial Date Filed 2012-03-05
Court District Court, N.D. California Date Terminated 2013-09-27
Cause 35:271 Patent Infringement Assigned To William Haskell Alsup
Jury Demand Both Referred To
Parties WATCHGUARD TECHNOLOGIES, INC.
Patents 10,066,003; 10,066,019; 10,115,021; 10,184,001; 10,232,015; 6,121,021; 7,265,009; 8,106,022; 8,183,024; 8,247,015; 8,269,019; 9,012,154; 9,040,088; 9,061,003; 9,061,064
Attorneys Roderick Bland Williams
Firms Lewis and Roca LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Network Protection Sciences, LLC v. Juniper Networks, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Network Protection Sciences, LLC v. Juniper Networks, Inc. (N.D. Cal. 2012)

Date Filed Document No. Description Snippet Link To Document
2013-01-13 189 administrator has given it operating rights to do so” (col 9:61–64 (emphasis added)). Fortinet’s …faulty. It is true that the patent used UNIX to describe an embodiment of the patent (see cols. …language of the patent, and is premised on Fortinet’s unduly narrow assumption that the patent … 18 In this patent infringement action involving network firewalls…construction of six phrases found in the asserted patent. On December 21, 2012, a tentative External link to document
2013-09-24 331 Exhibit arguments 38:20 253:20 12:14 13:10 66:3,4,4,5,7,14,21 94:13 247:14 antivirus … Q. Ever do any patent prosecution? 10 A. I run the patent program. I set …set up the 11 patent program and run the patent program at 12 Fortinet, but I don't -- so … for the 13 prosecution of patents, but I don't draft patents 14 myself. I review applications…issued patents. And there were a handful, I can't 10 remember how many, of patent applications External link to document
2013-09-25 332 Exhibit fairly excuse 60:8,10 66:19,25 70:22 71:3,5 54:18 103:10 50:19 133:1 …area of the '601 patent? 23 Q. So you read the '601 patent, 24 correct? 25… So there was a patent license on an 25 implementation of the patent, and so that would DEPOLINK… Does Elysium own any other patents, 6 other than the patents that have been issued 7 under…re-examination? 3 A. The patent office re-examines the 4 patents to determine whether or not it External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Dow
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.